Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (05.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 05.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
Stammdaten
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | Beam Therapeutics Inc. |
|---|---|
| Ticker | BEAM |
| CIK | 0001745999 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 3,15 Mrd. USD |
| Beta | 2,19 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 139,743,000 | -79,992,000 | -0.81 | 1,481,177,000 | 1,238,358,000 |
| 2025-09-30 | 10-Q | 9,698,000 | -112,728,000 | -1.10 | 1,311,081,000 | 966,002,000 |
| 2025-06-30 | 10-Q | 8,466,000 | -102,291,000 | -1.00 | 1,391,157,000 | 1,046,813,000 |
| 2025-03-31 | 10-Q | 7,470,000 | -109,270,000 | -1.24 | 1,466,920,000 | 1,123,136,000 |
| 2024-12-31 | 10-K | 63,518,000 | -376,742,000 | -4.58 | 1,103,824,000 | 733,545,000 |
| 2024-09-30 | 10-Q | 14,269,000 | -96,668,000 | -1.17 | 1,171,367,000 | 791,317,000 |
| 2024-06-30 | 10-Q | 11,772,000 | -91,051,000 | -1.11 | 1,261,266,000 | 854,094,000 |
| 2024-03-31 | 10-Q | 7,410,000 | -98,669,000 | -1.21 | 1,359,796,000 | 913,490,000 |
| 2023-12-31 | 10-K | 377,709,000 | -132,527,000 | -1.72 | 1,459,714,000 | 981,329,000 |
| 2023-09-30 | 10-Q | 17,193,000 | -96,088,000 | -1.22 | 1,290,534,000 | 778,941,000 |
| 2023-06-30 | 10-Q | 20,116,000 | -82,776,000 | -1.08 | 1,353,887,000 | 811,643,000 |
| 2023-03-31 | 10-Q | 24,208,000 | -96,460,000 | -1.33 | 1,332,352,000 | 761,506,000 |
| 2022-12-31 | 10-K | 60,920,000 | -289,088,000 | -4.13 | 1,341,714,000 | 733,474,000 |
| 2022-09-30 | 10-Q | 15,799,000 | -109,575,000 | -1.56 | 1,350,250,000 | 714,477,000 |
| 2022-06-30 | 10-Q | 16,652,000 | -71,950,000 | -1.02 | 1,418,375,000 | 800,161,000 |
| 2022-03-31 | 10-Q | 8,432,000 | -69,214,000 | -1.01 | 1,453,402,000 | 829,068,000 |
| 2021-12-31 | 10-K | 51,844,000 | -370,638,000 | -5.77 | 1,474,453,000 | 826,738,000 |
| 2021-09-30 | 10-Q | 763,000 | -28,118,000 | -0.42 | 1,156,555,000 | 853,814,000 |
| 2021-06-30 | 10-Q | 6,000 | -76,253,000 | -1.23 | 893,078,000 | 548,551,000 |
| 2021-03-31 | 10-Q | 6,000 | -201,560,000 | -3.35 | 693,241,000 | 422,429,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Evans John M. | Director, Officer, CEO | Open Market Sale | -30,078 | 24.58 | -739,317.24 | -229,7% | |
| 2026-04-01 | Simon Amy | Officer, Chief Medical Officer | Open Market Sale | -6,700 | 24.58 | -164,686.00 | -51,2% | |
| 2026-04-01 | Ciaramella Giuseppe | Officer, President | Open Market Sale | -11,810 | 24.58 | -290,289.80 | -90,2% | |
| 2026-03-31 | Evans John M. | Director, Officer, CEO | Open Market Sale | -25,000 | 22.76 | -569,085.00 | -176,8% | |
| 2026-03-30 | Evans John M. | Director, Officer, CEO | Open Market Sale | -25,000 | 22.37 | -559,230.00 | -173,8% | |
| 2026-02-24 | Ciaramella Giuseppe | Officer, President | Open Market Sale | -35,000 | 32.00 | -1,120,042.00 | -348,0% | |
| 2026-01-30 | Evans John M. | Director, Officer, CEO | Open Market Sale | -22,094 | 28.27 | -624,672.50 | -194,1% | |
| 2026-01-30 | Evans John M. | Director, Officer, CEO | Open Market Sale | -2,906 | 29.00 | -84,274.00 | -26,2% | |
| 2026-01-29 | Evans John M. | Director, Officer, CEO | Open Market Sale | -16,333 | 29.19 | -476,801.10 | -148,2% | |
| 2026-01-29 | Evans John M. | Director, Officer, CEO | Open Market Sale | -8,667 | 29.74 | -257,780.85 | -80,1% | |
| 2026-01-22 | Bellon Christine | Officer, Chief Legal Officer | Open Market Sale | -1,371 | 34.00 | -46,614.00 | -14,5% | |
| 2026-01-22 | Cavanagh Bethany J | Officer, SVP, Finance and Treasurer | Open Market Sale | -6,198 | 35.00 | -216,933.10 | -67,4% | |
| 2026-01-20 | Cavanagh Bethany J | Officer, SVP, Finance and Treasurer | Open Market Sale | -3,034 | 30.12 | -91,384.08 | -28,4% | |
| 2026-01-15 | Bellon Christine | Officer, Chief Legal Officer | Open Market Sale | -559 | 35.40 | -19,787.93 | -6,1% | |
| 2026-01-15 | Bellon Christine | Officer, Chief Legal Officer | Open Market Sale | -15,959 | 34.72 | -554,067.75 | -172,2% | |
| 2026-01-15 | Bellon Christine | Officer, Chief Legal Officer | Open Market Sale | -2,111 | 33.62 | -70,975.83 | -22,1% | |
| 2025-12-31 | Bellon Christine | Officer, Chief Legal Officer | Open Market Sale | -1,254 | 27.10 | -33,983.40 | -10,6% | |
| 2025-12-31 | Emany Sravan Kumar | Officer, Chief Financial Officer | Open Market Sale | -6,294 | 27.10 | -170,567.40 | -53,0% | |
| 2025-10-27 | FMR LLC | 10% Owner | Open Market Sale | -459 | 26.68 | -12,246.12 | -3,8% | |
| 2025-10-02 | Evans John M. | Director, Officer, CEO | Open Market Sale | -25,000 | 24.63 | -615,667.50 | -191,3% | |
| 2025-10-01 | Cavanagh Bethany J | Officer, SVP, Finance and Treasurer | Open Market Sale | -467 | 24.53 | -11,455.51 | -3,6% | |
| 2025-10-01 | Evans John M. | Director, Officer, CEO | Open Market Sale | -25,000 | 24.51 | -612,655.00 | -190,4% | |
| 2025-10-01 | Bellon Christine | Officer, Chief Legal Officer | Open Market Sale | -373 | 24.53 | -9,149.69 | -2,8% | |
| 2025-07-30 | FMR LLC | 10% Owner | Open Market Sale | -48,374 | 20.50 | -991,667.00 | -308,1% | |
| 2025-07-03 | Simon Amy | Officer, Chief Medical Officer | Open Market Sale | -876 | 20.12 | -17,625.12 | -5,5% | |
| 2025-07-01 | Simon Amy | Officer, Chief Medical Officer | Open Market Sale | -374 | 16.94 | -6,336.42 | -2,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.